Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Aditya Raghunath

Up 1,123% YTD, Is It Too Late to Buy This Breakout Biotech Stock?

The biotech space is incredibly exciting, given that companies are investing heavily to treat and prevent diseases. In fact, according to scientists, we might be in the golden age of biotechnology, making companies such as Summit Therapeutics (SMMT) top investment options right now. Several biotech players, including Summit Therapeutics, have strong drug candidates in clinical-stage trials on the cusp of approval. 

Shares of Summit Therapeutics have soared over 1,120% in 2024, valuing the company at a market cap of $22.4 billion. Let’s see if it's too late to buy this breakout biotech stock right now. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.